Nerve growth factor (NGF) treatment of Chinese hamster ovary ®broblast (CHO) cells exogenously expressing 2.5610 5 TrkA receptors (CHO/TrkA) results in inhibition of serum and insulin-like growth factor-I (IGF-I) stimulated cell proliferation in a dosedependent manner. Furthermore, NGF does not stimulate [ 3 H]thymidine incorporation and inhibits IGF-I mediated DNA synthesis in CHO/TrkA cells. NGF and IGF-I induce extracellular-signal regulated kinase 1 (ERK1) and ERK2 activation, but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I. Cotreatment with NGF and IGF-I yields an ERK1/2 activity pro®le similar to that of NGF treatment alone. While pretreatment with mitogen activated protein kinase kinase (MKK) inhibitor PD98059 (30 mM) results in 100% inhibition of IGF-I stimulated MAPK phosphorylation (IC 50 51 mM), NGF mediated MAPK phosphorylation is only decreased by 50% (IC 50 =3 mM). NGF, but not IGF-I, stimulates tyrosine phosphorylation and activation of PLC-g1 which can be inhibited in a dose-dependent manner by phosphoinositide-speci®c phospholipase C (PI-PLC) inhibitor U73122 (IC 50 =4 mM). Pretreatment with U73122 (IC 50 =7 mM) results in an 87% inhibition of NGF mediated MAPK phosphorylation, while cotreatment with PD98059 and U73122 results in 97% inhibition. U73122 pretreatment has no eect on NGF stimulated Akt activation. NGF, but not IGF-I, stimulates the tyrosine phosphorylation of Suc1-associated neurotrophic factor-induced tyrosine phosphorylation target (SNT-1)/®broblast growth factor receptor substrate 2 (FRS2) which can be completely prevented by pretreatment with 10 mM U73122. Finally, inhibition of PI-PLC results in NGF's ability to stimulate DNA synthesis in the absence and presence of IGF-I.
Nerve growth factor (NGF) treatment of Chinese hamster ovary ®broblast (CHO) cells exogenously expressing 2.5610 5 TrkA receptors (CHO/TrkA) results in inhibition of serum and insulin-like growth factor-I (IGF-I) stimulated cell proliferation in a dosedependent manner. Furthermore, NGF does not stimulate [ 3 H]thymidine incorporation and inhibits IGF-I mediated DNA synthesis in CHO/TrkA cells. NGF and IGF-I induce extracellular-signal regulated kinase 1 (ERK1) and ERK2 activation, but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I. Cotreatment with NGF and IGF-I yields an ERK1/2 activity pro®le similar to that of NGF treatment alone. While pretreatment with mitogen activated protein kinase kinase (MKK) inhibitor PD98059 (30 mM) results in 100% inhibition of IGF-I stimulated MAPK phosphorylation (IC 50 51 mM), NGF mediated MAPK phosphorylation is only decreased by 50% (IC 50 =3 mM). NGF, but not IGF-I, stimulates tyrosine phosphorylation and activation of PLC-g1 which can be inhibited in a dose-dependent manner by phosphoinositide-speci®c phospholipase C (PI-PLC) inhibitor U73122 (IC 50 =4 mM). Pretreatment with U73122 (IC 50 =7 mM) results in an 87% inhibition of NGF mediated MAPK phosphorylation, while cotreatment with PD98059 and U73122 results in 97% inhibition. U73122 pretreatment has no eect on NGF stimulated Akt activation. NGF, but not IGF-I, stimulates the tyrosine phosphorylation of Suc1-associated neurotrophic factor-induced tyrosine phosphorylation target (SNT-1)/®broblast growth factor receptorIntroduction Nerve growth factor and insulin-like growth factor-I stimulate the activation of a large array of identical signal transduction molecules through their respective transmembranous tyrosine kinase receptors. However, the biological eects elicited by these ligands and their receptors are quite distinct. In vivo, NGF is involved in the survival and maintenance of the cholinergic neurons of the basal forebrain and of neural crest derived sensory and sympathetic neurons of the peripheral nervous system, whereas IGF-I plays a critical role in skeletal and cartilage growth. This is re¯ected in vitro by NGF's ability to promote neuronal dierentiation, associated with cessation of proliferation and the survival of the pheochromocytomaderived PC12 (Greene and Tischler, 1976) and other cell lines. In contrast, IGF-I's eects in vitro are mitogenic. In our CHO/TrkA cell culture system NGF exerts anti-proliferative eects while IGF-I stimulates mitogenesis, thus allowing us to investigate mechanisms underlying these growth factors' abilities to elicit opposing eects on cell proliferation.
MAP kinases represent a family of serine/threonine kinases which have been implicated in many tyrosine kinase receptor signal transduction pathways. Extracellular signal-regulated kinases, including ERK1 and ERK2, are members of the MAPK family and their activation requires tyrosine and threonine phosphorylation at two sites within the kinases' activation loop (Anderson et al., 1990; Zhang et al., 1995; Payne et al., 1991) . Their activation is regulated by the dual speci®city kinase family MKK which in turn is activated by serine/threonine kinases of the Raf family, including c-Raf-1 (Dent et al., 1992; Kyriakis et al., 1992) and B-Raf (Stephens et al., 1992) . Upon activation, the ERK MAPKs can activate RSK, the 90 kD ribosomal S6 protein and cytosolic phospholipase A 2 and, furthermore, can translocate to the nucleus to phosphorylate several transcription factors including Elk-1, Ets-2, c-Myc, NF-IL6/C/EBPb/NF-M, Tal-1 and perhaps STAT proteins (Seth et al., 1991; Gille et al., 1995; Janknecht et al., 1993; Kowenz-Leutz et al., 1994; Marais et al., 1993; Wadman et al., 1994; Wen et al., 1995; Yang et al., 1996) . Dierences in kinetics of ERK1 and ERK2 activation have been correlated with distinct biological eects elicited by growth factor stimulation in the PC12 cell line (Dikic et al., 1994; Traverse et al., 1994) .
In our non-neuronal ®broblast system we are also able to demonstrate dierential activation of ERK1 and ERK2 with NGF and IGF-I treatment accompanied by opposing eects on cell proliferation. These ®ndings prompted us to investigate mechanisms by which MAPK phosphorylation is regulated by NGF and IGF-I. Speci®cally, we investigated the roles of MKK and PLC-g1 in NGF and IGF-I mediated MAPK phosphorylation, and discovered that these two ligands employ distinct mechanisms in the regulation of the ERK1 and ERK2 enzymes. Furthermore, we demonstrate that NGF, but not IGF-I, is able to mediate tyrosine phosphorylation of SNT-1/FRS2 (Rabin et al., 1993; Kouhara et al., 1997) , and that this phosphorylation event is regulated by PI ± PLC. Finally, we show that inhibition of NGF stimulated PI ± PLC releases NGF's anti-mitogenic properties. Together, our ®ndings highlight mechanisms by which two very similar signal transduction pathways elicited by NGF and IGF-I can direct distinct biological outcomes.
Results
The eect of NGF on CHO/TrkA cell proliferation
We transfected the cDNA encoding human TrkA into CHO cells and generated stable clones expressing 2.5610 5 cell surface TrkA receptors. To determine NGF's eects on cell proliferation, cell count assays were performed for 5 days in the presence of 0.5% and 10% fetal calf serum. NGF inhibits serum stimulated proliferation in a dose-dependent manner ( Figure 1a , left panels). By day 5, 50 ng/ml NGF inhibits 0.5% serum stimulated proliferation by 88+2.6% (CHO/ TrkA#77) and 93+1.4% (CHO/TrkA#129) and 10% serum stimulated proliferation by 86.5+0.4% (CHO/ TrkA#77) and 89.9+0.1% (CHO/TrkA#129). These anti-proliferative eects were not clonally speci®c as we observed the same eects in six additional clones (data not shown). No inhibitory eect on serum stimulated growth was observed in parental CHO cells (Figure 1a , right panels), indicating that the anti-proliferative eect observed in CHO/TrkA cells is mediated through the TrkA receptor. We investigated this ®nding further by measuring NGF's eect on IGF-I stimulated proliferation mediated through the 5610 4 endogenous IGF-I receptors. NGF inhibited IGF-I (100 ng/ml) stimulated proliferation in CHO/TrkA cells in a dose-dependent manner ( Figure 1b , left panels) without any eects in parental CHO cells (Figure 1b , right panels). Fifty ng/ ml NGF impaired IGF-I mediated growth by 93+1.9% (CHO/TrkA#77) and by 96.5+1% (CHO/ TrkA#129). CHO/TrkA cells grow more slowly in the presence of serum and IGF-I compared to parental CHO cells. We believe this is due to the basal level of TrkA phosphorylation that is observed in the absence of NGF (data not shown); nonetheless, serum and IGF-I do elicit strong mitogenic eects in these cells, indicating that they are capable of responding appropriately to growth promoting stimuli. NGF did not alter [ 125 I]IGF-I binding to its endogenous receptors (data not shown), indicating that NGF's inhibitory eect must be occurring at the post-receptor level.
NGF's eect on DNA synthesis
Since it has been previously shown that NGF is mitogenic and transforming in another ®broblast cell line, NIH3T3 cells expressing TrkA (Cordon-Cardo et al., 1991) , we were surprised by NGF's antiproliferative eects in our long-term cell proliferation (Figure 2b) .
Activation of the ERK1 and ERK2 MAP kinases
It has been previously suggested that the kinetics of MAPK activation may dictate whether or not a growth factor stimulates cell cycle progression or differentiation, accompanied by cell cycle arrest (Traverse et al., 1992; Marshall, 1995) . Recent studies indicate that the duration and intensity of MAPK activation correlate with distinct biological eects elicited by growth factors in PC12 cells; sustained activation of MAPK in PC12 cells is associated with neurite outgrowth whereas transient MAPK activation correlates with mitogenesis (Dikic et al., 1994; Traverse et al., 1994) . Therefore, since NGF and IGF-I mediate opposing eects on CHO/TrkA cell proliferation, we measured the kinetics of MAPK activation in response to these growth factors. Maximal concentrations of NGF and IGF-I both stimulate MAPK activation in CHO/TrkA cells, but to dierent extents. Fifty ng/ml NGF induces a 2.8-fold increase in MAPK activation (Figure 3 , top panel) in comparison to a 0.8 fold increase elicited by 100 ng/ml IGF-I (Figure 3 , center panel) 10 min following addition of the respective growth factor. After 30 min MAPK activation is still 75% of maximal and gradually returns to basal levels by 4 h poststimulation. This is in strong contrast to IGF-I stimulated MAPK activation which declines by 72% after 30 min. Higher concentrations of IGF-I (i.e. 200 ng/ml) do not stimulate a higher level of MAPK activation than the already maximal dose of 100 ng/ml (data not shown). Interestingly, when both growth factors are simultaneously added the MAPK activation pro®le closely resembles that generated by NGF treatment alone (Figure 3 , bottom panel). Dierent kinetics and intensities of MAPK activation, therefore, correlate with opposing biological eects on CHO/ TrkA proliferation elicited by these two growth factors.
Regulation of ERK MAPK phosphorylation by a MKK sensitive pathway
To better understand how NGF and IGF-I differentially activate ERK1 and ERK2 we investigated mechanisms which regulate the phosphorylation of these enzymes. We observe a clear dierence in the ability of PD98059, a MKK inhibitor, to inhibit NGF vs IGF-I stimulated MAPK phosphorylation. Thirty minute pretreatment with PD98059 results in a decrease in NGF and IGF-I stimulated MAPK phosphorylation (Figure 4a and b, upper panels), as measured by Western blot analysis using an anti-active MAPK antibody, which recognizes only the dually phosphorylated active form of MAPK. As depicted in the lower panels, equal amounts of protein were loaded, as determined by reprobing of the same membranes with an ERK1 antibody. Concentrations as low as 1 mM of PD98059 completely inhibited IGF-I stimulated MAPK phosphorylation whereas, even at 30 mM, NGF stimulated MAPK phosphorylation was inhibited by only 50% (IC 50 =3 mM). Although we do not prove that NGF activated MKK activity is completely inhibited our data demonstrate that NGF mediated MAPK phosphorylation is dierentially regulated compared to IGF-I. This possibly occurs through an additional MKK independent mechanism, which is insensitive to PD98059 pretreatment.
NGF, but not IGF-I, stimulates tyrosine phosphorylation and activation of PLC-g1
In pursuit of ®nding a MKK independent mechanism that contributes to NGF stimulated MAP kinase phosphorylation, we investigated the potential role of PLC-g1 in this enzymatic event. We investigated NGF's and IGF-I's ability to stimulate PLC-g1 tyrosine phosphorylation and activation. Immunoprecipitation experiments using anti-PLC-g1 antibodies, followed by Western blotting analysis with an antiphosphotyrosine antibody, demonstrate that NGF, but not IGF-I, stimulates tyrosine phosphorylation of PLC-g1. NGF mediated tyrosine phosphorylation is initiated by 1 min and can be observed even 60 min after stimulation ( Figure 5a ). IGF-I mediated PLC-g1 tyrosine phosphorylation was never observed during the 60 min time-course ( Figure 5b , top panel). PLC-g1 is clearly detectable in these immunoprecipitates, as indicated by reprobing of the membrane with anti-PLC-g1 antibody ( Figure 5b , center panel). In addition, IGF-I was active in this experiment as we can demonstrate IGF-I stimulated MAPK phosphorylation in the supernatants ( Figure 5b , bottom panel). We also investigated NGF's and IGF-I's ability to activate PLC-g1 by measuring the hydrolysis of PI(4,5)P 2 to inositol 1,4,5-trisphosphate (IP 3 ) by immunoprecipitated PLC-g1. Maximal PLC-g1 activation is observed at 10 min and persists up to 60 min following NGF stimulation, whereas no activation is observed with IGF-I treatment ( Figure 5c ). Interestingly, the timecourse of PLC-g1 activation mimics that of NGFmediated MAPK activation.
Regulation of ERK MAPK phosphorylation by a PI-PLC-sensitive pathway
To determine whether NGF activated PLC-g1 contributes to MKK independent MAP kinase activation, we performed experiments with the PI ± PLC inhibitor U73122 (Smith et al., 1990) . U73122 inhibits NGF stimulated PLC-g1 associated PI(4,5)P 2 hydrolysis in a dose-dependent manner with an IC 50 of 4 mM ( Figure   6a ). A 10 min pretreatment with U73122 also inhibits NGF stimulated MAPK phosphorylation in a dosedependent manner, whereas the inactive analog U73343 (Smith et al., 1990) , even at 10 mM, has no eect on NGF stimulated MAPK phosphorylation ( Figure 6b , top panels), demonstrating the speci®city of U73122. Densitometric analysis of the results obtained with U73122 yields an IC 50 value of 7 mM ( Figure 6b , lower panel). To further address the speci®city of U73122, we measured its eect on NGF stimulated Akt activation (Andjelkovic et al., 1998; Ulrich et al., 1998) . Akt (PKB or RAC protein kinase) is a downstream target of PI3-kinase (Burgering and Coer, 1995) and should, therefore, not be inhibited by a PLC inhibitor. Neither U73122, nor U73343, (Figure 6c , lower panel). Together these data indicate that NGF stimulated MAPK phosphorylation can occur by a PI ± PLC dependent pathway. The ability of: (1) NGF to stimulate tyrosine phosphorylation and activation of PLC-g1; (2) the coinciding time-courses of PLC-g1 and MAPK activation; (3) the ability of U73122, an inhibitor of PLC-g1, to inhibit NGF stimulated MAPK phosphorylation but not Akt activation; and (4) the presence of a PLC-g1 consensus binding site (Songyang et al., 1993) in the TrkA receptor make PLC-g1 an attractive candidate as a regulator of NGF mediated MAPK activation. If PLC-g1 mediated MAPK activation occurs via a MKK independent pathway one would predict that cotreatment with the MKK and the PLC-g1 inhibitors will results in additive inhibitory eects on NGF stimulated MAPK activation. We, therefore, treated cells with each of the compounds alone and in combination, prior to 10 min NGF treatment, and again measured the eects on MAPK phosphorylation. Thirty mM PD98059 and 10 mM U73122 inhibit NGF stimulated MAPK phosphorylation by 39 and 66%, respectively and, together, achieve almost complete (97%) inhibition (Figure 7 ), indicating that U73122 is blocking NGF mediated MAPK phosphorylation via a MKK independent pathway. We, therefore, propose that the ability of NGF to employ at least two independent pathways leading to MAPK phosphorylation contributes to the stronger and more sustained level of MAPK activation observed in comparison to IGF-I.
NGF stimulates SNT-1/FRS2 phosphorylation in a PI ± PLC dependent manner
In an eort to investigate additional mechanisms by which NGF may be exerting its anti-proliferative eects in the presence and absence of IGF-I, we analysed the tyrosine phosphorylation of the SNT-1/ FRS2 protein in response to NGF and IGF-I. It has been previously shown that growth factors which stimulate neurite outgrowth in PC12 cells, such as NGF and FGF, but not mitogens such as EGF, induce the tyrosine phosphorylation of an approximately 78 ± 90 kD protein which is precipitated from cell lysates by virtue of its association with p13 (Rabin et al., 1993) . p13 tightly associates with p34, a protein implicated in regulation of the cell cycle. Thus, it is likely that SNT-1/FRS2, as part of this multiprotein complex, also plays a role in regulating cell cycle progression. We observed that NGF, but not IGF-I, mediates tyrosine phosphorylation of an 80 ± 90 kD protein which associates with p13 suc -agarose (Figure 8 ). Furthermore, this tyrosine phosphorylation is also evident when cells are cotreated with NGF and IGF-I. Since NGF is able to inhibit IGF-I stimulated mitogenesis, it is possible that this tyrosine phosphorylation event plays a role in preventing cell cycle progression. Interestingly, NGF stimulated tyrosine phosphorylation of SNT-1/FRS2 can be speci®cally inhibited by the PI ± PLC inhibitor U73122. Pretreatment with the inactive analog MKK inhibitor PD98059 or with U73343 (data not shown) had no eect on NGF mediated SNT-1/FRS2 tyrosine phosphorylation. 
U73122 inhibits NGF's anti-mitogenic eects
If PLC-g1 does in fact regulate the anti-proliferative eects of NGF one would predict that its inhibition with U73122 will inhibit NGF's anti-mitogenic actions. We ®nd that pretreatment with 1.5 mM U73122, but not U73343, results in a 2.6-fold increase of NGF stimulated [ 
Discussion
Although NGF and IGF-I initiate their biologic eects through receptor tyrosine kinases which engage similar sets of downstream signalling molecules, their ultimate eects are quite dierent, with IGF-I causing proliferation and NGF stimulating dierentiation. To study the mechanisms responsible for these divergent eects, we transfected CHO cells, which express abundant endogenous IGF-I receptors with TrkA cDNA to create stable cell lines expressing both IGF-I and TrkA receptors. We found that IGF-I stimulated proliferation of CHO/TrkA cells, whereas NGF did not, and that NGF completely inhibited the proliferative eects of IGF-I. We found that the time-course of MAPK stimulation was quite dierent between these two growth factors. NGF led to a higher and more prolonged activation, while the eect of IGF-I was smaller and quite transient. In fact, 2 h after NGF stimulation, MAPK activity was still as great as the peak eect of IGF-I (at 10 min).
These ®ndings suggested some fundamental differences in the signalling pathways leading to MAPK from TrkA compared to the IGF-I receptor. In this regard, we found that IGF-I stimulated MAPK activity was completely abolished by pretreatment with the MKK inhibitor, whereas the NGF eect on MAP kinase activity was only reduced by 50%. It has been shown previously in other cell types that PLC-g1 associates with and is tyrosine phosphorylated by TrkA (Vetter et al., 1991; Obermeier et al., 1993; Loeb et al., 1994; Ohmichi et al., 1991a,b; Kim et al., 1991) in response to NGF stimulation. Since we showed that PLC-g1 is also tyrosine phosphorylated and activated in response to NGF but not IGF-I in CHO/TrkA cells, we investigated the role of this enzyme as a potential regulator of NGF stimulated MAPK phosphorylation. We found that pretreatment with the PI-PLC inhibitor U73122 led to inhibition of NGF stimulated MAPK phosphorylation, while its inactive but close structural analogue U73343 yielded no inhibition on this NGF mediated eect. How does PI-PLC inhibition by U73122 result in decreased MAP kinase phosphorylation induced by NGF? PDGF receptor mutant studies suggest a role for PLC-g1 in PDGF mediated Ras activation (Valius and Kazlauskas, 1993) . Furthermore, Duckworth and Cantley (1997) report that PKC, which lies downstream of PLC-g1, contributes to PDGF stimulated MAPK activity in a Raf-1 independent manner. Since PLC-g1 binds to and is activated by TrkA, this molecule may also play a role in NGF mediated Ras and, therefore, MAPK activation. In fact, Stephens et al. (1994) showed that MAPK activity depends on the Shc and PLC-g1 TrkA binding site in PC12 cells. Activated PLC catalyzes the hydrolysis of PI(4,5)P 2 to generate the second messengers IP 3 and diacyl glycerol (DAG) (Griendling et al., 1986) . IP 3 induces the release of Ca 2+ from intracellular stores (Berridge, 1987) , while DAG activates protein kinase C. (PKC) (Nishizuka, 1988) . It has been shown that PKC can directly phosphorylate Raf-1 (Kolch et al., 1993), and in lymphocytes it has been demonstrated that PKC downregulates GAP activity toward Ras and, thereby, contributes to Ras activation (Downward et al., 1990) . Inhibition of PI-PLC with U73122 could, therefore, result in decreased MAP kinase phosphorylation due to inhibition of PKC-mediated activation of Ras and Raf.
Cotreatment with PD98059 and U73122 resulted in additive inhibitory eects on NGF stimulated MAPK Figure 4 Eect of PD98059 on NGF and IGF-I stimulated MAPK phosphorylation. CHO/TrkA cells were treated with indicated concentrations of PD98059 or DMSO 30 min prior to a 10 min stimulation with (a) 50 ng/ml NGF or (b) 100 ng/ml IGF-I. Cell lysates were subjected to SDS ± PAGE on 10% acrylamide gels and to Western blot analysis with anti-active MAPK antibody (upper panels), followed by reprobing of the same membranes with ERK1 antibody (lower panels) phosphorylation. Since PD98059 inhibits MKK1 with a tenfold lower IC 50 than MKK2 (Alessi et al., 1995) , it is possible that NGF mediated activation of MAP kinase also involves MKK2 which shares 90% amino acid homology with MKK1. Evidence that MKK2 activation may be involved in NGF stimulated signal transduction can be found in an experiment performed by Pang et al. (1995) . Pretreatment with PD98059 resulted in a 50% decrease in NGF stimulated MKK activity precipitated with MKK antisera that are immunoreactive with both isoforms of MKK. Since PD98059 is highly speci®c for MKK1, the remaining MKK activity could be attributed to MKK2. PD98059 pretreatment leads to a decrease in NGF stimulated MAPK phosphorylation by preventing Raf activation of MKK1; further inhibition could then be achieved by Figure 5 Dierential stimulation of PLC-g1 tyrosine phosphorylation and activation by NGF and IGF-I. (a) CHO/TrkA cells were stimulated for the indicated times with 50 ng/ml NGF, followed by immunoprecipitation using mixed polyclonal anti-PLC-g1 antibodies as described in Materials and methods. The tyrosine phosphorylation state of immunoprecipitated PLC-g1 was detected by Western blotting with antiphosphotyrosine antibody PY20. (b) CHO/TrkA cells were stimulated with 100 ng/ml IGF-I for indicated times, followed by immunoprecipitation of PLC-g1. The pellets were subjected to Western blot analysis using antiphosphotyrosine antibody PY20 (top panel). After stripping this membrane, it was reprobed with anti-PLC-g1 antibody to veryify equal protein loading (middle panel). The supernatants were subjected to Western blot analysis using anti-Active MAP kinase antibody to verify IGF-I activity. Stimulation with 50 ng/ml NGF for 10 min was included as a positive control. (c) CHO/TrkA cells were treated with 50 ng/ml NGF or 100 ng/ml IGF-I for the indicated times. The phospholipase C activity of immunoprecipitated PLC-g1 was assayed as described in Materials and methods. Values represent means+s.e.m. of triplicates U73122 whih may act to decrease Ras or Raf activation, ultimately inhibiting MKK2 mediated MAPK phosphorylation. The additive inhibitory eects of the two pharmacological compounds could also be the result of a novel U73122 sensitive pathway that mediates Raf-independent MKK or MAPK activation.
It has been previously demonstrated that differentiating factors, such as NGF and FGF, can stimulate the tyrosine phosphorylation of a 78 ± 90 kD protein (SNT) in PC12 cells, whereas mitogens such as EGF are not capable of mediating this event (Rabin et al., 1993) . Recently, human SNT-1 has been cloned, and although the detailed cloning information has not been published, Xu et al. (1998) state that it is the human homologue of murine FRS2 (Kouhara et al., 1997) . Kouhara et al. (1997) also believe that the FRS2 protein is identical to SNT-1, as FRS2 antibodies recognize the p13 sucl -agarose precipitated SNT-1 protein by Western blot. In an eort to further understand mechanisms by which NGF and IGF-I exert differential eects in CHO/TrkA cells we analysed the tyrosine phosphorylation state of this protein in response to these growth factors. NGF, but not IGF-I, was capable of stimulating tyrosine phosphorylation of SNT-1/FRS2; furthermore, SNT-1/FRS2 phosphorylation by NGF also occurred in the presence of IGF-I. We were also able to demonstrate that the PLC inhibitor U73122, but not the MKK inhibitor PD98059, prevents NGF stimulated tyrosine phosphorylation of this protein. It appears, therefore, that SNT-1/FRS2 lies downstream of PLC in the NGF signal transduction pathway. Interestingly, Kouhara et al. (1997) found that FRS2 overexpression results in an enhancement in MAPK activation through a Rasdependent mechanism. Therefore, tyrosine phosphorylation of SNT-1/FRS2 by NGF, but not by IGF-I, may be a further mechanism by which NGF is able to stimulate more intense and prolonged MAPK activation and thereby exert its anti-proliferative eects.
A central question in this ®eld has been,`How do growth factors elicit distinct biological eects while activating a plethora of identical signalling proteins?' One of the main dierences in the NGF and IGF-I signal transduction pathways in CHO/TrkA cells is the exclusive activation of PLC-g1 by NGF. Inhibition of PLC-g1 results in NGF-mediated biological eects that mimicked those elicited by IGF-I, i.e. incorporation, converting NGF from an anti-mitogenic to a mitogenic factor. This is consistent with the ability of U73122 to augment EGF's mitogenic responses in NR6 ®broblast cell lines (Chen et al., 1996) . We, therefore, propose that PLC-g1 plays a key role in providing speci®city to the NGF signalling pathway, potentially due to its ability to modulate MAPK activation.
Since CHO/TrkA cells do not extend neurites in response to NGF, they provide a useful system for investigating NGF's anti-mitogenic eects in the absence of the cytoskeletal changes associated with neurite outgrowth in PC12 cells. We were surprised to observe NGF induced growth arrest in CHO/TrkA ®broblasts, in the presence of serum and IGF-I, since it has been shown previously that NGF is transforming in NIH3T3 ®broblasts exogenously expressing TrkA (Cordon-Cardo et al., 1991) . The reason for diering results between our CHO ®broblast system and the NIH3T3 system is unclear, but recently it was demonstrated that NGF induces growth arrest in another NIH3T3 cell line that expresses TrkA (Decker, 1995) . Perhaps dierences in expression levels of receptors or experimental protocol may explain these contradicting results.
We found that the basal growth rate of all screened CHO/TrkA clones is decreased compared to parental CHO cells. This observation may have important mechanistic implications. We showed that in the presence of NGF, MAPK levels remained activated for longer periods of time than with IGF-I. Since we also detect low levels of MAPK activation in the absence of NGF, we suspect that when maintained for long periods of time this is enough to induce the growth inhibitory eects observed with NGF.
The precise mechanism by which NGF triggers exit from the cell cycle is unclear, but it has been demonstrated that NGF stimulation results in an increase in the cyclin dependent kinase inhibitory protein p21
Cip1/WAF1 (Yan and Zi, 1997; Dobashi et al., 1995; Decker, 1995) whereas mitogens, such as insulin or EGF, do not (Yan and Zi, 1995) . Interestingly, Pumiglia and Decker recently demonstrated that this NGF dependent long term induction of p21 Cip1/WAF1 increase is regulated by the MKK/MAPK pathway (Pumiglia and Decker, 1997) , thus establishing a link between NGF mediated MAP kinase activation and exit from the cell cycle. Since expression levels of p21
Cip1/WAF1 and its state of activation play a critical role in dictating either cell cycle progression or cell cycle exit, the duration and strength of growth factor mediated MAPK activation could play a critical role Figure 7 Eect of PD98059 and U73122 on NGF stimulated MAPK phosphorylation. CHO/TrkA cells were treated for 30 min as indicated prior to 50 ng/ml NGF stimulation for 10 min. Whole cell lysates were subjected to SDS ± PAGE followed by Western blotting analysis using the anti-active MAPK antibody (top panel). This blot was stripped and reprobed with the anti-ERK1 antibody to demonstrate equal protein loading (middle panel). Densitometric analysis showing the mean values+s.d. of this experiment and another independent experiment are shown in the bottom panel. PD98059 was used at 30 mM, and U73122 and U73343 at 10 mM Figure 8 Tyrosine phosphorylation of SNT-1/FRS2 in CHO/ TrkA cells. CHO/TrkA cells were treated with the indicated conditions, followed by SNT-1/FRS2 precipitation with p13 sucagarose and Western blotting with antiphosphotyrosine antibody PY20 as described in Materials and methods. Pretreatment with 30 mM PD98059 or 10 mM U73122 occurred 30 and 20 min, respectively, prior to growth factor stimulation Figure 9 The eect of U73122 on growth factor stimulated [ 3 H]thymidine incorporation. CHO/TrkA cells starved for 72 h in 0.1% BSA containing media were treated with 1.5 mM U73122, 1.5 mM U73343 or DMSO vehicle for 20 min followed by addition of 50 ng/ml NGF and/or 100 ng/ml IGF-I for 18 h. [ in the outcome of these events. It will be interesting to determine if the NGF stimulated PI ± PLC dependent pathway also plays a role in p21
Cip1/WAF1 induction. It has been proposed that when MAPK activation is sustained, MAPK translocates to the nucleus whereas transient and weaker MAPK does not (Traverse et al., 1992; Nguyen et al., 1993) . However, weaker and transient MAPK activation is necessary for mitogenesis, a process that also requires transcriptional regulation. Perhaps detection of MAPK translocation during growth factor mediated mitogenesis, requires an assay of higher sensitivity, allowing for the detection of fewer MAPK molecules in the nucleus.
The fact that NGF is able to override IGF-I's proliferative eects may have important implications in growth factor treatment of disease states, as one growth factor can interfere with signalling pathways initiated by another. Furthermore, it highlights the tight regulation of receptor and growth factor expression in the same cell that must occur during normal development and aging. IN, USA) . p13suc-agarose conjugate was purchased from Calbiochem (La Jolla, CA, USA). U73122 (1 -[6 -[[17 -beta -3 -methoxyestra -1,3,5(10)-trien-17-yl] amino] hexyl]-1H-pyrrole-2,5-dione) and U73343 (1-[6-[[17-beta-3-methoxyestra -1,3,5(10) -trien -17 -yl] amino]hexyl]-2,5-pyrrolidine) were obtained from Calbiochem-Novabiochem (La Jolla, CA, USA). Recombinant protein A agarose was purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA). SuperSignal chemiluminescent substrate stable peroxide solution was obtained from Pierce (Rockford, IL, USA). Phosphatidylcholine and phosphatidylethanolamine were bought from Avanti Polar Lipids (Alabaster, AL, USA). Outdated human platelets were purchased from the San Diego Blood Bank (San Diego, CA, USA). IGF-I was generously donated by B Frank at Eli Lily (Indianapolis, IN, USA).
Materials and methods

Reagents
Antibodies
Anti-ACTIVE MAPK polyclonal antibody (V6671) was purchased from Promega (Madison, WI, USA). Monoclonal p44 ERK1 antibody (M12320) and monoclonal PY-20 antiphosphotyrosine antibody were obtained from Transduction Laboratories (Lexington, KY, USA). Polyclonal anti-PLC-g1 antibodies (SC-81) and anti-rabbit IgG-HRP were bought from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mixed monoclonal PLC-g antibodies (05-163) were obtained from Upstate Biotechnology Inc. (Lake Placid, NY, USA). The PhosphoPlus-Akt (Ser473) antibody kit (9270) was purchased from New England Biolabs (Beverly, MA, USA).
Generation of stable CHO/TrkA cells
Plasmid pDM69 was digested with EcoRI to excise the human TrkA cDNA insert. The ends of the insert were blunted and ligated into the polylinker region of the EcoRV digested CLDN vector. CHO cells were transfected with this plasmid via the lipofectamine method followed by G418 selection (500 mg/ml). Clonal cell lines were established and individual clones were screened for TrkA expression by 125 I-NGF binding and Western blotting with anti-TrkA antibodies. Characterization of these cells was described previously (Zapf-Colby and Olefsky, 1998) .
Cell proliferation assay
CHO/TrkA cells were seeded at approximately 3610 4 cells/ 35 mm well in complete medium. The following day the medium was replaced with medium containing 0.5% or 10% FCS plus appropriate concentrations of growth factors. Cells of duplicate wells were trypsinized and counted each day for 5 days using a hemacytometer. Media and growth factors were replaced every other day.
[
H]Thymidine incorporation
Cells were seeded at a density of 3610 5 cells/well in six well plates in complete medium. Twenty-four hours later cells were starved for 72 h in serum free medium containing 0.1% BSA. Growth factor stimulation occurred for 18 h. During the last 14 h 0.5 mCi [ 3 H]thymidine was added per well. Cells were placed on ice and after media aspiration, washed twice each with PBS and 10% TCA, and once with 95% ethanol. Cells were lysed with 1 ml 0.4 M NaOH, neutralized with 1 ml 0.4 M HCl and counted in a b-counter.
MAPK activity assay
Cells were seeded in 60 mm dishes and grown to 80% con¯uency. After growth factor stimulation at 378C, cells were washed twice with ice-cold PBS/100 mM sodium orthovanadate, scraped into 500 ml 250 mM sucrose/20 mM HEPES/1 mM EDTA (pH 7.4), centrifuged 5 min at 1000 g and resuspended in 20 ml lysis buer (30 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 1% TX-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 800 KIU/ml aprotinin, 1 mM leupeptin, 1 mM sodium orthovanadate, 160 mM sodium¯uoride). Protein concentrations were determined using BioRad protein assay solution and samples were boiled in 0.33 volume 46Laemmli buer. Fifty mg samples were subjected to SDS ± PAGE using 10% SDS ± acrylamide gels containing 0.45 mg/ml myelin basic protein. Gels were soaked 2615 min in 100 ml 20% 2-propanol/ 50 mM HEPES, pH 7.6, 5 mM b-mercaptoethanol/50 mM HEPES, 6 M Urea/5 mM b-mercaptoethanol/50 mM HEPES. Renaturation was initiated by removing 50 ml of urea buer and adding 50 ml of renaturation buer (0.05% Tween 20/ 5 mM b-mercaptoethanol/50 mM HEPES). This step was repeated for a total of four times. After complete buer removal, gels were soaked in 150 ml renaturation buer for 15 min, and again O/N at 48C. Gels were soaked in 100 ml cold incomplete reaction buer for 30 min at 48C followed by an incubation at 308C with 25 ml kinase reaction buer/gel for 1 ± 2 h. Gels were soaked 4660 min and then O/N at RT in 150 ml wash buer. The following day, gel was soaked in 5% methanol/40% glycerol solution for 15 min and then the gels were dried, exposed to Phosphor-Imager screen O/N. Intensities of 44 and 42 kD (ERK1/2) bands were quantitated using a phosphorimager.
MAPK phosphorylation
Cells were seeded in 60 mm plates and starved the following day for 72 h in serum-free HAMS/F12 medium containing 0.1% BSA. Cells were pretreated with PD98059 or DMSO for 30 min, or U73122 and U73343 for 10 min at 378C, followed by stimulation with 50 ng/ml NGF or 100 ng/ml IGF-I for 10 min. Cells were immediately placed on ice, rinsed once with ice-cold PBS, and lysed in 500 ml 26Laemmli buer containing 2 mM sodium orthovanadate and 100 mM sodium¯uoride. Approximately 50 mg protein were subjected to standard 10% SDS ± PAGE followed by transfer onto Immobilon for 16 h at 27 V. The membranes were blocked in TBS/0.05% Tween 20/1%BSA for 1 h followed by incubation with the anti-active MAPK polyclonal antibody at 1 : 20 000 in TBS/0.05% Tween 20/ 0.1%BSA for 2 h at RT. After a 30 min incubation with anti-rabbit IgG-HRP, the membrane was washed several times in TBS/0.05% Tween 20 for a total of 1 h, and subjected to ECL. Blots were stripped for 10 min in 0.5 M acetic acid/0.5 M NaCl at RT and reprobed with the monoclonal anti-ERK1 antibody to verify equivalent protein loading.
Assay for PLC-g1 activity CHO/TrkA cells were treated with 50 ng/ml NGF for the indicated times. Cells were sonicated at 48C in PLC assay buer containing 5 mM Tris-HCl, pH 7.0, 75 mM KCl, 0.416 mM CaCl 2 0.4 mM EGTA, 0.1 mM NaN 3 , and 10 mg/ ml leupeptin, 10 mg/ml aprotinin, 1 mM sodium orthovanadate and 1 mM phenylmethylsulfonyl¯uoride. After centrifugation at 15 000 g for 10 min, PLC-g1 was immunoprecipitated (1.5 mg protein) with 4 mg polyclonal anti-PLC-g1 antibodies (SC-81) for 2 h followed by an overnight incubation with recombinant Protein A agarose. The immunoprecipitates were washed three times by resuspension in PLC assay buer. The phospholipase C activity of immunoprecipitated PLC-g1 was assayed as described previously (Goldschmidt-Clermont et al., 1991) for the puri®ed enzyme with minor modi®cations. Brie¯y, the immunoprecipitates were incubated at 378C for 60 min in PLC assay buer (100 ml ®nal volume) containing 0.5 mM dithiothreitol and small unilamellar liposomes. The liposomes were prepared by sonication and composed of 30 mM cholesterol, 50 mM phosphatidylcholine, 30 mM phosphatidylethanolamine, 5 mM PIP 2 , 25 000 d.p.m. of labelled PIP 2 and 10 mM pro®lin. As described previously (Janmey, 1991) , pro®lin was puri®ed from human platelets by polyproline anity chromatography and preincubated with the sonicated liposomes.
SNT precipitation
Cells were seeded in 60 mm plates and starved the following day for 48 h in serum-free HAMS/F12/0.1% BSA. If required, cells were pretreated with PD98059 or U73312 as described above. Cells were stimulated for various times with growth factors at 378C and immediately placed on ice. After lysing in 500 ml lysis buer and incubating on ice for 30 min, 50 ml of p13-agarose were added per sample and allowed to incubate 2 h at 48C. After centrifugation at 14 000 r.p.m., the agarose pellets were washed four times with ice-cold lysis buer. Fifty ml of 26Laemmli buer containing phosphatase inhibitors were added to each pellet and boiled for 10 min. Samples were subjected to standard 7.5% SDS ± PAGE followed by a 4 h transfer onto Immobilon at 250 mAmps. Western blotting was performed by blocking in TBS/0.1% Tween 20/2.5% BSA for 1 h at RT and incubating with PY20 antibody at 1 : 1000 in blocking buer. After a 30 min incubation with anti-mouse-HRP (1 : 1000) in TBS/0.1% Tween and 4615 min washes in TBST, SuperSignal was used according to manufacturer's instructions.
Inhibitors
PD98059 was reconstituted at 10 mM in 100% DMSO, stored in aliquots at 7708C, thawed just prior to use at 0.1 ± 30 mM. U73122 and U73343 were stored at 3.33 mM in 100% DMSO at 7208C and thawed immediately prior to use at 0.1 ± 10 mM.
